Latest / Cleveland Clinic Cancer Advances
Pre-Taxane Lutetium in Prostate Cancer: Changing the Treatment Algorithm
Is there a role for earlier integration of lutetium PSMA therapy in mCRPC management? Emerging evidence supports its use in the pre-taxane setting, prompting a shift in sequencing decisions. This episode outlines patient selection, PSMA imaging requirements and how to balance disease aggressiveness, tolerability and real-world considerations when choosing between lutetium and chemotherapy.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.